Changing up CMS model codes improves payment outcomes

A recent study published in JAMA Open Network found that using individual codes and present on admission designations instead of group codes can improve the predictability of patient total payment within 30 days of a hospitalization.

Yale researchers looked at nearly 2 million Medicare fee-for-service hospitalizations and compared the risk models from CMS and using present on admission codes and single diagnosis codes and separation of index admission codes. They found that changes to the candidate variables in CMS models improved the risk models predicting patient total payment for a 30-day period after hospitalization for three conditions––acute myocardial infarction (AMI), heart failure (HF) and pneumonia.

And changing the models could have bigger impacts.

“Better models can potentially improve research, benchmarking, public reporting and calculations for population-based programs,” wrote first author Harlan M. Krumholz, MD, SM, of the Department of Health Policy and Management at Yale School of Public Health, and colleagues.

The mean risk standardized payment for the regular CMS models was $23,105, compared to $23,211 for the individual-codes model. The new model better identified people at the ends of the payment spectrum, the researchers wrote.

“The individual-codes models produced better discrimination, goodness of fit, and predictive range, with similar calibration,” Krumholz et al. wrote. “…Our findings suggest that there are opportunities for improvements in the predictive performance of these models with relatively simple changes in the candidate variables.”

Amy Baxter

Amy joined TriMed Media as a Senior Writer for HealthExec after covering home care for three years. When not writing about all things healthcare, she fulfills her lifelong dream of becoming a pirate by sailing in regattas and enjoying rum. Fun fact: she sailed 333 miles across Lake Michigan in the Chicago Yacht Club "Race to Mackinac."

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.